NASDAQ$NAMS

NewAmsterdam Pharma Company NV · Q1 2025 earnings

Q1 2025 earnings · · Before market open · Investor relations

Briefing

NewAmsterdam Pharma reported Q1 2025, revenue of $3M, a net loss of $39.5M, diluted EPS of ($0.34).

For Q1 2025, NewAmsterdam Pharma reported revenue of $3M, a net loss of $39.5M, diluted EPS was ($0.34). The filing highlights segment performance, liquidity, and management commentary on the period.

  • Revenue $3M.
  • Net loss $39.5M.
  • Diluted EPS ($0.34).

Headline financials

Total Revenue

$2.98M

Previous: $1.4M+112.6%
EPS (adj)

-$0.34

Previous: -$1.06+67.9%
Research and Development Expenses

$44.8M

No prior period
Selling, General and Administrative Expenses

$27.2M

No prior period
Total Operating Expenses

$71.9M

No prior period
Net Loss

-$39.5M

No prior period
Marketable Securities

$60.1M

No prior period
Total Current Assets

$817M

No prior period
Total Current Liabilities

$40.9M

No prior period
Total Shareholders' Equity

$777M

No prior period
Net Cash Used in Operating Activities

-$36.5M

No prior period
Net Cash Provided by Investing Activities

$2.86M

No prior period
Net Cash Provided by Financing Activities

$6.52M

No prior period
Interest Income

$7.35M

No prior period
Fair Value Change - Earnout

$3.99M

No prior period
Fair Value Change - Warrants

$13.8M

No prior period
Foreign Exchange Gains/(Losses)

$4.29M

No prior period
Net Income

-$39.5M

Previous: -$93.8M+57.8%
Operating Income

-$68.9M

Previous: -$55.5M-24.2%

Revenue & EPS history

NewAmsterdam Pharma · Revenue · Quarterly

$2.98M

Q1 2025+112.6%vs Q1 2024
Beat estimate in 4 of 6 quarters(67%)
ActualEstimate

Forward guidance

Management discusses operating priorities, capital allocation, and sector risks in the quarterly filing.

Tailwinds

  • Headline results and segment trends anchor the quarter.
  • Liquidity and balance-sheet capacity support operations.
  • Strategic initiatives outlined in MD&A.

Headwinds

  • Macro, rates, or input costs may pressure margins.
  • One-time items affect year-over-year comparability.
  • Execution risk on growth or restructuring plans.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 17 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

+0.8%

Avg return

Earnings day

+3.0%

Avg return

5 days after

-0.6%

Avg return

30 days after

59%

10 / 17 earnings

Positive

+18.2%

Q3 2024

Best reaction

-9.6%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+1.2%+25.4%+1.5%
Q4 2025-3.0%+2.6%-17.9%
Q3 2025+4.3%+6.7%-3.5%
Q1 2025+1.2%-8.3%-3.2%
Q4 2024+10.2%+13.4%+21.7%
Q3 2024+18.2%+28.4%-4.2%
Q1 2024-9.6%-12.1%-7.8%
Q2 2023-5.7%-4.9%-2.4%
Q4 2023-5.7%-4.9%-2.4%
Q1 2023+0.3%+2.0%-0.9%
Q4 2022+2.1%+1.7%+7.4%
Q3 2022-0.1%+0.1%+0.8%
Q2 2022+0.1%+0.1%+0.4%
Q1 2022+0.0%+0.1%+0.3%
Q3 2021-0.3%+0.2%-0.1%
Q2 2021+0.2%+0.2%-1.2%
Q1 2021+0.1%+0.2%+1.0%
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro